This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trapasso, F.
Right arrow Articles by Fusco, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trapasso, F.
Right arrow Articles by Fusco, A.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, December 2000, p. 9236-9246, Vol. 20, No. 24
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Rat Protein Tyrosine Phosphatase eta  Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1

Francesco Trapasso,1 Rodolfo Iuliano,1 Angelo Boccia,2 Antonella Stella,1 Roberta Visconti,3 Paola Bruni,2 Gustavo Baldassarre,2 Massimo Santoro,3 Giuseppe Viglietto,2 and Alfredo Fusco*,1

Dipartimento di Medicina Sperimentale e Clinica, Facoltà di Medicina e Chirurgia di Catanzaro, Università degli Studi di Catanzaro "Magna Graecia," 88100 Catanzaro,1 and Istituto dei Tumori di Napoli2 and Centro di Endocrinologia ed Oncologia Sperimentale del CNR, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II,"3 80131 Naples, Italy

Received 15 March 2000/Returned for modification 13 June 2000/Accepted 27 September 2000


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The r-PTPeta gene encodes a rat receptor-type protein tyrosine phosphatase whose expression is negatively regulated by neoplastic cell transformation. Here we first demonstrate a dramatic reduction in DEP-1/HPTPeta (the human homolog of r-PTPeta ) expression in a panel of human thyroid carcinomas. Subsequently, we show that the reexpression of the r-PTPeta gene in highly malignant rat thyroid cells transformed by retroviruses carrying the v-mos and v-ras-Ki oncogenes suppresses their malignant phenotype. Cell cycle analysis demonstrated that r-PTPeta caused G1 growth arrest and increased the cyclin-dependent kinase inhibitor p27Kip1 protein level by reducing the proteasome-dependent degradation rate. We propose that the r-PTPeta tumor suppressor activity is mediated by p27Kip1 protein stabilization, because suppression of p27Kip1 protein synthesis using p27-specific antisense oligonucleotides blocked the growth-inhibitory effect induced by r-PTPeta . Furthermore, we provide evidence that in v-mos- or v-ras-Ki-transformed thyroid cells, the p27Kip1 protein level was regulated by the mitogen-activated protein (MAP) kinase pathway and that r-PTPeta regulated p27Kip1 stability by preventing v-mos- or v-ras-Ki-induced MAP kinase activation.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

A key mechanism in the regulation of cell growth and differentiation is the phosphorylation of proteins on tyrosine residues, which is controlled by two families of enzymes: protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). Both families include transmembrane receptor-like and cytoplasmic molecules (11, 15, 43, 45, 46). It is well established that PTKs are positive regulators of cell growth. Much less is known about the role of PTPs in cell proliferation although there is evidence that the genes encoding them act as tumor suppressor genes. In fact, a receptor-type PTP encoded by the RPTPgamma gene, which maps on human chromosome 3, is deleted in renal and lung tumor cell lines (20). Moreover, the expression of PTP1B in fibroblasts transformed by the neu oncogene significantly inhibits oncogenic transformation (4). Similarly, the leukocyte common-antigen-related PTP (LAR) reduced the in vitro proliferation and tumor growth of a breast carcinoma cell line transformed by the neu oncogene (48). Finally, receptor-like PTPs such as PTPµ and PTPkappa promote cell-cell aggregation through homophilic binding interactions and associate with cadherin-catenin complexes, which suggests that they are involved, through their effect on cell-cell contact stabilization, in the control of cadherin adhesive properties (3, 7). A dual-specificity phosphatase gene (PTEN) has been implicated in Cowden disease (a rare autosomal dominant hamartoma syndrome associated with a high risk of breast and thyroid carcinomas) (22, 27, 29) and Bannayan-Zonana syndrome, another familiar hamartoma syndrome (26). Moreover, there is a high frequency of PTEN mutations in several sporadic cancers (21, 41), and PTEN suppresses the growth of a glioma cell line (8). We have isolated a gene encoding a receptor-type PTP from a normal rat thyroid cell line, PC Cl 3 (49). This PTP gene was named the r-PTPeta gene because of its homology with the human DEP-1/HPTPeta gene (14, 31). The predicted protein contains a unique intracellular catalytic domain, a short transmembrane domain, and an extracellular region containing eight fibronectin type III-like repeats. The r-PTPeta gene is expressed in almost all normal rat and mouse tissues and cells but not in cultured mouse and rat fibroblasts (19, 49). Like genes whose expression is thyroid specific, the r-PTPeta gene is positively regulated by thyrotropin through the protein kinase A pathway and is negatively regulated by protein kinase C activation (28). In addition, r-PTPeta gene expression was reduced in all oncogene-transformed cells and was absent from highly malignant thyroid cells (30). The aim of this study was to investigate whether the r-PTPeta gene exerts growth-inhibiting activity and to clarify the molecular mechanisms whereby r-PTPeta regulates cell growth. First, we demonstrate that DEP-1/HPTPeta (the human homolog of r-PTPeta ) expression was dramatically reduced in a panel of human thyroid malignant neoplasias. Subsequently, we show that the r-PTPeta gene suppresses the malignant phenotype of rat thyroid cells transformed by retroviruses carrying the v-mos and the v-ras-Ki oncogenes (9, 10). Reverted cells contained increased levels of p27Kip1 protein, a cyclin-dependent kinase inhibitor involved in the regulation of the G1/S transition (33, 38, 44). This effect was dependent on a decreased rate of proteasome-dependent degradation. Since the arrest of cell growth induced by r-PTPeta was impaired when p27Kip1 protein synthesis was blocked, we propose that r-PTPeta ability to inhibit transformed cell growth is mediated by an increase in the half-life of protein p27Kip1.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Construction of r-PTPeta expression vectors. A cDNA containing the entire open reading frame of r-PTPeta (49) was cloned into the EcoRI site of the retroviral vector pMV-7 (25). We also prepared an r-PTPeta mutant carrying a Cys 1118/Ser mutation in the catalytic domain. PCR fragments containing the required mutation were generated by recombinant PCR (13) using pGEM3Z/r-PTPeta (wild type) as the template.

Other expression vectors. The full-length PTPgamma cDNA was cloned in the pXT1 expression vector (40). p27Kip1 coding sequences were obtained from differentiated NT2/D1 cells by reverse transcriptase-PCR (RT-PCR), which was performed according to the manufacturer's instructions (Perkin-Elmer Cetus). Amplified DNA was cloned into the pCRII vector (Invitrogen Inc.) and sequenced. Subsequently, the p27Kip1 coding sequence was cloned into the pcDNA 3 expression vector (Invitrogen Inc.) under the control of the cytomegalovirus promoter (1).

Cell culture and transfection experiments. PC Cl 3, PC MPSV, FRTL-5 Cl 2, and FRTL KiMSV cell lines are described elsewhere (10). They were grown in Coon's modified F-12 medium (Life Technology), supplemented with 5% calf serum (GIBCO) and a mixture containing six growth factors (1 mU of thyrotropin (TSH)/ml, 10 nM hydrocortisone, 100 nM insulin; 5 µg of transferrin/ml, 5 nM somatostatin, 20 µg of glycyl-histidyl-lysine/ml). Transfections were obtained with the calcium phosphate procedure as described previously (12).

RNA isolation and Northern blot analysis. Total RNA was extracted by the RNAfast isolation system (Molecular Systems, San Diego, Calif.). Northern blotting and hybridization are described elsewhere (36). The probes were a 728-bp XhoI-XhoI fragment corresponding to the intracellular region of the r-PTPeta cDNA, the v-mos oncogene (2); the v-ras-Ki oncogene (10), the p27Kip1 probe, obtained as described above, and the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) probe, obtained by RT-PCR amplification as described in the next paragraph.

RT-PCR analysis. Two micrograms of DNase-treated total RNA was reverse transcribed using random hexanucleotide primers (1 µM), 0.2 mM deoxynucleoside triphosphates (dNTPs), 40 U of RNAsin, and 30 U of avian myeloblastosis virus reverse transcriptase in 1× RT buffer (Promega) in a total volume of 25 µl. One microliter of cDNA was amplified in a 100-µl reaction mixture in 1× PCR buffer (Promega) containing 0.2 mM dNTPs, 1.5 mM MgCl2, 0.5 µM (each) primer, and 2.5 U of Taq DNA polymerase (Promega). For the thyroglobulin (TG), thyroperoxidase (TPO), TSH receptor (TSH-R), thyroid transcription factor 1 (TTF-1), and PAX-8 cDNA, 20 amplification cycles (93°C for 1 min, 55°C for 1 min, 72°C for 1 min) were performed with the following oligonucleotide primers. For TG the forward primer was 5'-TCAACGTGTTTGTCCCTGAG-3' and the reverse primer was 5'-GGTCTGAGCTTCATTGAGAA-3', corresponding to nucleotides 1451 to 1470 and 1982 to 2001, respectively, of the rat TG sequence (GenBank accession no. X02318). For TPO the forward primer was 5'-ACAAGTGTGTCTTCCCAGAG-3' and the reverse primer was 5'-CTATGCAGCCTTGGACTGAT-3', corresponding to nucleotides 1751 to 1770 and 2430 to 2450, respectively, of the rat TPO sequence (GenBank accession no. M31655). For TSH-R the forward primer was 5'-ATCATCGGTTTCGGCCAAGA-3' and the reverse primer was 5'-CAGTGTGTACACTGATAACT-3', corresponding to nucleotides 1141 to 1160 and 1571 to 1590, respectively, of the rat TSH-R sequence (GenBank accession no. M34842). For PAX-8 the forward primer was 5'-CAAGGTGGTGGAGAAGATA-3' and the reverse primer was 5'-AAGATGCTTTCGAGGACCA-3', corresponding to nucleotides 303 to 321 and 702 to 720, respectively, of the rat PAX-8 sequence (GenBank accession no. X94246). For TTF-1 the forward primer was 5'-TCTGCCAGCAAAGAGAGCTT-3' and the reverse primer was 5'-TACAGCTACAAGTTCACATC-3', corresponding to nucleotides 1851 to 1870 and 2052 to 2071, respectively, of the rat TTF-1 sequence (GenBank accession no. X53858). To express the rat GAPDH gene, which served as the internal control for the amount of cDNA in the PCR, we amplified a 430-bp cDNA fragment with the following oligonucleotide primers: forward, 5'-TCACCATCTTCCAGGAGCGAG-3'; reverse, 5'-ACAGCCTTGGCAGCACCAGT-3'. To verify the absence of contamination of RNA samples with DNA, we performed the PCR on samples that were processed identically to the target samples, but that were not reverse transcribed. Then 20 µl of PCR products was blotted and hybridized with specific 32P-radiolabeled probes.

Assay of the transformed state. The tumorigenicities of the cell lines were tested by injecting 2 × 106 cells subcutaneously into athymic mice. Soft-agar colony assays were performed as described elsewhere (24).

Flow-cytometric assay. Wild-type and r-PTPeta -transfected cells were analyzed for DNA content as previously described (18). Cells were collected and washed in phosphate buffer solution. DNA was stained with propidium iodide (50 µg/ml) and analyzed with a FACScan flow cytometer (Becton Dickinson, San Jose, Calif.) interfaced with a Hewlett-Packard (Palo Alto, Calif.) computer. Cell cycle data were analyzed with the CELL-FIT program (Becton Dickinson).

Colony assay. Cells were seeded at a density of 2 × 106 cells per 100-mm-diameter dish. The next day, cells were transiently transfected with pCDNA3, pCMV-p27, or the r-PTPeta gene by the calcium phosphate procedure as described previously (12). Forty-eight hours posttransfection, cells were split and selected in G418 (Life Technologies). Two weeks later, cells were stained with 500 µg of crystal violet/ml in 20% methanol and the colonies were counted. A colony assay was performed by transfecting the r-PTPeta gene in the presence of p27-AS (5'-GACACTCTCACGTTTGACAT-3', corresponding to nucleotides 1 to 20 of the p27Kip1 rat coding sequence [GenBank accession no. D83792]) (5) phosphorothioate oligodeoxynucleotides.

Immunoblotting analysis. Cells were scraped in phosphate buffer solution and lysed in Nonidet P40 (NP-40) lysis buffer supplemented with 50 mM NaF, 0.5 mM Na3VO4, 0.5 mM phenylmethylsulfonyl fluoride, and 5 µg of aprotinin and 5 µg of leupeptin/ml. Proteins (50 µg) were separated on polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) filter membranes. Membranes were blocked in 5% nonfat dry milk, incubated with primary antibodies (anti-p27 and anti-p21 [Transduction Laboratories] and antiphosphotyrosine [Amersham, Inc.]) detected by the appropriate secondary antibodies, and revealed by enhanced chemiluminescence (ECL; Amersham Inc.). For DEP-1 detection, we used antibodies raised against synthetic peptide QPKYAAELANRGK, specific for the juxtamembrane region of DEP-1. They were affinity purified against the peptide. For r-PTPeta protein detection, we used antibodies raised against the intracellular region of r-PTPeta expressed as a recombinant protein fused to glutathione S-transferase and affinity purified. The antibodies used were C-18 (anti-PTPgamma ), F234 (anti-K-ras) (Santa Cruz Biotechnology Inc.), and 149-177 (anti-c-mos) (Calbiochem).

Mitogen-activated protein (MAP) kinase (extracellular signal-regulated kinases 1 and 2 [ERK1 and -2]) immune complexes were prepared by immunoprecipitation with anti-MAP kinase antibodies (Santa Cruz Biotechnology Inc.) and collected on protein A-Sepharose beads, washed, and incubated in kinase buffer at 30°C as described previously (16). The reaction was terminated by sodium dodecyl sulfate (SDS) sample buffer; the phosphorylated substrates were separated by SDS-12.5% polyacrylamide gel electrophoresis and quantified by PhosphorImager (GS; Bio-Rad).

Preparation and phosphorylation of recombinant p27Kip1. A fragment of PCR-amplified human p27Kip1 cDNA containing the full-length coding region was subcloned into the pET21a vector (Novagen) yielding a construct that encodes p27Kip1 tagged with hexahistidine at the C terminus. The protein was expressed in BL21 cells and purified using Ni nitrilotriacetic acid resin (Qiagen) as described previously (33).

In vitro p27Kip1 degradation assay. Cell extracts from 106 cells were lysed in ice-cold bidistilled water, homogenized, and incubated with 1 µg of recombinant p27Kip1/ml in the presence of ubiquitin, ATP, and the ATP regeneration system, as previously described (23). In brief, 1 µg of recombinant p27Kip1 protein was incubated with 100 µg of proteasome extracts from PC Cl 3, PC MPSV, and PC MPSV/r-PTPeta cells for 12 h and then loaded onto a 12.5% polyacrylamide gel, transferred to nitrocellulose membranes, and revealed by anti-p27Kip1 antibodies.

BrdU incorporation. The bromodeoxyuridine (BrdU) incorporation assay was performed as follows. Cells (5 × 105) were plated into 60-mm-diameter dishes and allowed to attach for 24 h in the presence or absence of anti-p27Kip1 antisense oligonucleotides. The labeling procedure was carried out for 1 h at 37°C as recommended by manufacturer (Roche Molecular Biochemicals). Fluorescence was visualized with a Zeiss 140 epifluorescence microscope equipped with filters allowing discrimination between Texas red and fluorescein.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

DEP-1/HPTPeta protein levels are drastically reduced in human thyroid carcinomas. To determine the relevance of r-PTPeta in human thyroid neoplasias, we analyzed DEP-1/HPTPeta (the r-PTPeta human homolog) protein levels in a panel of surgically removed human thyroid carcinomas (16 papillary carcinomas, 5 follicular carcinomas, and 4 anaplastic carcinomas) by Western blotting. Three samples of normal thyroid tissue served as controls. The level of DEP-1/HPTPeta protein was determined by densitometric analysis of films. The DEP-1/HPTPeta protein was detectable in all normal thyroid tissues, whereas it was not detectable in the large majority of thyroid carcinomas (22 of 25), and it was present, but in drastically reduced amounts in one papillary carcinoma and two follicular carcinomas. A representative Western blot is shown in Fig. 1. The 220-kDa DEP-1 protein was detected in the normal thyroid tissues (NT1 and NT2), whereas in most of the carcinoma samples no band can be detected, apart from one of papillary carcinoma sample (lane 9). In two follicular carcinomas a very weak band was detected (lanes 16 and 17). Contamination of the the tumors by adjacent normal tissue might account for this result. DEP-1 mRNA expression (data not shown) parallels the protein expression, which suggests that the block of DEP-1 expression occurs at the mRNA level. These results suggest that DEP-1/HPTPeta down-regulation may represent a common pathway in the development of thyroid carcinomas and prompted us to investigate whether PTPeta exerts growth-inhibiting activity in thyroid cells.


View larger version (26K):
[in this window]
[in a new window]
  		FIG. 1.   Expression of the DEP-1/HPTPeta protein in normal and neoplastic thyroid tissues. Western blot analysis of DEP-1/HPTPeta protein expression in thyroid tumor tissue. Total proteins (50 µg) were resolved by SDS-7% PAGE, transferred to nitrocellulose filters and probed with anti-DEP-1 antibodies. NT1 and NT2, two different normal thyroid tissues. Lanes 1 to 4, anaplastic carcinomas; lanes 5 to 13, papillary carcinomas; lanes 14 to 17, follicular carcinomas. C, control PC MPSV cells transfected with the r-PTPeta gene. Anti-gamma -tubulin antibodies were used to ensure uniform gel loading.

The expression of the r-PTPeta gene induces morphological reversion of transformed rat thyroid cells. To restore r-PTPeta gene expression in transformed rat thyroid cells, the r-PTPeta full-length cDNA was cloned into eukaryotic expression vector pMV-7, under the transcriptional control of the long terminal repeat of Moloney murine leukemia virus (see Materials and Methods). The pMV-7 vector carries the gene for resistance to G418 as a selectable marker. As a negative control we used a construct that carries the full-length cDNA of the gene with a point mutation in the catalytic region at position 3353. The mutation replaces cysteine 1118 with serine (r-PTPeta C/S), which inactivates the enzymatic activity of PTP proteins (43) (Fig. 2).


View larger version (24K):
[in this window]
[in a new window]
  		FIG. 2.   Schematic representation of the plasmids used in this study. The wild-type (WT) and mutated r-PTPeta C/S cDNAs were inserted into the pMV-7 vector, which carries the gene for resistance to G418 as a selectable marker. The r-PTPeta C/S construct was derived from the wild-type r-PTPeta gene by coding sequence change resulting in a Cys-to-Ser mutation at position 1118 of the associated protein. This mutation abolished enzymatic activity. The domains of the r-PTPeta protein are indicated. LTR, long terminal repeat; NEO, neomycin resistance gene.

We used the FRTL KiMSV and PC MPSV cells, carrying the v-ras-Ki and v-mos oncogenes, respectively, to investigate the potential tumor suppressor activity of the r-PTPeta gene. These cells have a highly malignant phenotype and lack r-PTPeta gene expression as demonstrated by Northern blotting (reference 49 and references therein) (Fig. 3) and RT-PCR analyses (R. Iuliano, unpublished results). The FRTL KiMSV and PC MPSV cells were transfected with the wild-type and r-PTPeta C/S constructs. The transfected cells were selected for resistance to G418, and several clones as well as the mass population were analyzed for r-PTPeta gene expression by Northern blot hybridization and Western blot analysis (Fig. 3).


View larger version (46K):
[in this window]
[in a new window]
  		FIG. 3.   Northern blot and Western blot analysis of the expression of the endogenous and exogenous r-PTPeta gene in normal, transformed, and r-PTPeta -transfected thyroid cells. (A) Northern blots. Total RNA (20 µg/lane) was extracted from PC Cl 3, PC MPSV/r-PTPeta clones 1, 2, and 3, PC MPSV/pMV-7, PC MPSV, and PC MPSV/r-PTPeta C/S clones 1 and 2 (left) and PC MPSV/r-PTPgamma clones 1 and 2 (right) and hybridized to radiolabeled r-PTPeta or GAPDH cDNAs, as indicated. (B) Western blots. Total proteins (20 µg/lane) were extracted from the cells used for panel A and hybridized with anti-r-PTPeta protein, anti-v-mos, or anti-gamma -tubulin antibodies. (C) Northern blots. Total RNA (20 µg/lane) was extracted from FRTL-5, FRTL-5 KiMSV/r-PTPeta clones 1, 2, and 3, FRTL KIMSV, FRTL KIMSV/pMV-7, and FRTL KiMSV/r-PTPeta C/S clones 1 and 2 (left) and FRTL KIMSV r-PTPeta clones 1 and 2 (right) and hybridized to radiolabeled r-PTPeta or GAPDH cDNAs as indicated. (D) Western blots. Total proteins (20 µg/lane) were extracted from the cells used for panel C and hybridized with anti-r-PTPeta protein, anti-Ki-ras, or anti-gamma -tubulin antibodies, respectively.

As shown, both constructs were efficiently expressed in cells, without a gross difference in expression between them, both at mRNA (Fig. 3A and C) and protein (B and D) levels. Moreover, the expression of the exogenous wild-type r-PTPeta gene (lower band) was comparable to (in some cell clones even higher than) that of the endogenous gene (larger band; 7.0 kb) that we detected in the normal PC Cl 3 and FRTL-5 Cl 2 cells. Finally, we observed no difference in the levels of expression of v-mos and v-ras-Ki between the parental and r-PTPeta -transfected cells (Fig. 3B and D). Interestingly, exogenous r-PTPeta gene expression did not result in reexpression of the endogenous r-PTPeta gene.

To determine the effects exerted by r-PTPeta on the growth and differentiation of malignant thyroid cells, we used three clones that have high r-PTPeta expression. PC MPSV and FRTL KiMSV cell clones transfected with r-PTPeta C/S and the backbone vector were used as a control. All the clones showed the same biological behavior. Therefore, the data shown here refer to one or two representative clones.

Reintroduction of the r-PTPeta gene into the v-mos and v-ras-Ki oncogene-transformed cells induced dramatic morphological changes. As shown in Fig. 4, the PC MPSV/r-PTPeta cells lost their typical round shape and became more adherent to the culture dish and less refractile. The changes in FRTL KiMSV transfected cells were equally significant, although less dramatic with respect to the PC MPSV r-PTPeta -transfected cells. Conversely, no changes were observed in the same neoplastic cells transfected with the r-PTPeta C/S mutant construct or with the backbone vector. It is noteworthy that the morphology of PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells was different from that of uninfected normal thyroid cells. To demonstrate the specificity of the r-PTPeta effects, the PC MPSV and FRTL KiMSV cells were also transfected with the pMV-7 vector carrying the PTPgamma gene. Even though significant expression was observed in the transfected cells (Fig. 3C), no morphological changes were observed (Fig. 4).


View larger version (96K):
[in this window]
[in a new window]
  		FIG. 4.   Morphology of normal, transformed, and r-PTPeta -transfected thyroid cells. (A) Phase-contrast photomicrographs of normal thyroid cells (PC Cl 3), transformed thyroid cells (PC MPSV), transformed thyroid cells transfected with the wild-type r-PTPeta gene (PC MPSV/r-PTPeta ), and transformed thyroid cells transfected with r-PTPeta C/S or the r-PTPgamma gene (PC MPSV/r-PTPeta C/S and PC MPSV/r-PTPgamma , respectively). (B) Phase-contrast photomicrographs of normal thyroid cells (FRTL-5 Cl 2), transformed thyroid cells (FRTL KiMSV), transformed thyroid cells transfected with the wild-type r-PTPeta gene (FRTL KiMSV/r-PTPeta ), and transformed thyroid cells transfected with the mutant r-PTPeta C/S or r-PTPgamma gene (FRTL KiMSV/r-PTPeta C/S and FRTL KiMSV/r-PTPgamma , respectively). PC MPSV/pMV-7 and FRTL KiMSV/pMV-7 cell lines were obtained after transfection of transformed thyroid cells with backbone vector pMV-7. Magnification, ×150.

The r-PTPeta gene suppresses the malignant phenotype of the v-ras-Ki- and v-mos-transformed rat thyroid cells. We analyzed the malignant phenotype of the r-PTPeta -transfected PC MPSV and FRTL KiMSV cells by evaluating their colony-forming efficiencies in soft agar and their tumorigenicities in athymic mice. PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells did not grow in soft agar or generate tumors when injected into nude mice. In contrast, like the untransfected cells, PC MPSV and FRTL KiMSV cells transfected with the mutated r-PTPeta construct, with the backbone vector, or with PTPgamma had high colony-forming efficiencies in soft agar and induced tumors in athymic mice with a short latency period (about 2 weeks). The results are summarized in Table 1.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Analysis of the neoplastic phenotype of rat thyroid MPSV- and KiMSV-transformed cells transfected with r-PTPeta gene

r-PTPeta gene expression partially restores thyroid differentiation markers in transformed cells. To verify whether suppression of the neoplastic phenotype was associated with reacquisition of the differentiated phenotype, the r-PTPeta -transfected cells were analyzed for the expression of the TG, TPO, and TSH-R genes by a semiquantitative RT-PCR assay. Figure 5 shows that low expression of the TG, TSH-R, and TPO genes was restored in the PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells recovered. Conversely, no expression was observed in the transformed thyroid cells transfected with the mutated r-PTPeta construct or with the empty vector. Interestingly, the switch-on of the TPO and TG genes in the r-PTPeta -transfected cells was associated with reexpression of the TTF-1 and PAX-8 genes, which are the main regulators of TG (47). As previously demonstrated (9, 10), these differentiation markers are switched off in v-mos- and v-ras-Ki-transformed thyroid cells. (Fig. 5). However, restoration of thyroid cell differentiated functions was only partial since the expression of the TG and TPO genes was at a level that is 1/100 that of the wild-type cells, as demonstrated by densitometric analysis (data not shown). To exclude the effects of contamination, the RT-PCR experiments were repeated four times using different RNA preparations.


View larger version (87K):
[in this window]
[in a new window]
  		FIG. 5.   Analysis of thyroid-specific gene expression by RT-PCR in PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells. The levels of TG, TPO, TSH-R, TTF-1, and PAX-8 mRNA were determined by RT-PCR (for details see Materials and Methods). The cDNAs were coamplified with GAPDH, as an internal control. Bands of comparable intensities, obtained by GAPDH coding sequence-specific primers, indicate comparable amplification of all samples. No bands were seen in non-reverse-transcribed RNAs, thus excluding DNA contamination (data not shown). The sources of the RNAs are indicated.

The r-PTPeta gene induces a significant reduction in the growth rate of transformed thyroid cells and partially restores contact inhibition mechanisms. We also investigated the changes induced by reexpression of r-PTPeta on the growth potential of PC MPSV and FRTL KiMSV cells. To measure quantitatively the effects exerted by r-PTPeta and the proliferative potential of the cells, we used cytofluorimetry to determine the S-phase fraction and the extent of response to contact inhibition in parental and r-PTPeta -transfected cells. The results showed that PC MPSV cells (Fig. 6A) had a dramatic reduction of the fraction in the G1 phase compared to normal PC Cl 3 cells (40.0 and 66.3%, respectively); this was mirrored by an increase in S-phase cells (32.7 and 14.6%, respectively). Conversely, the fraction of cells in G1 phase was significantly increased (63.8%) and the number of cells in S-phase was greatly reduced (21.9%) in reverted PC MPSV/r-PTPeta cells. r-PTPeta expression in the ras-transformed FRTL cells analyzed at low density has almost no effect on their cell cycle distribution (Fig. 6B).


View larger version (42K):
[in this window]
[in a new window]
  		FIG. 6.   Flow-cytometric analysis of normal, transformed, and r-PTPeta -transfected rat thyroid cells. The DNA contents of transformed and r-PTPeta -transfected cells were analyzed by flow cytometry after propidium iodine staining. (A) PC Cl 3, PC MPSV, and PC MPSV/r-PTPeta cells. (B) FRTL-5, FRTL KiMSV, and FRTL KiMSV/r-PTPeta cells.

When we analyzed normal and transformed cells for growth arrest by contact inhibition by flow cytometry, we observed that those from normal cell lines PC Cl 3 and FRTL-5 Cl 2 were almost completely growth arrested at confluency, with more than 90% of cells entering quiescence (Fig. 6). However, upon transformation by v-mos or v-ras-Ki oncogenes, rat thyrocytes lost contact inhibition. Indeed most cells continued to proliferate (as demonstrated by the elevated amount of S-phase cells) and detached from the plates. Strikingly, r-PTPeta partially restored the molecular mechanisms that led to contact inhibition of thyroid cells, as demonstrated by the increased G1 fraction and reduced S-phase fraction of PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells (when they reached confluency) compared with PC MPSV and FRTL KiMSV cells, respectively.

The r-PTPeta gene induces a significant change in the pattern of tyrosine phosphorylation of transformed thyroid cells. We investigated whether r-PTPeta expression in transformed rat cells induced significant changes in the pattern of tyrosine phosphorylation. As shown in Fig. 7A, transformation of thyroid PC Cl 3 cells by v-mos induced an increase in the phosphorylation of tyrosine residues of some bands and, in some cases, the appearance of newly phosphorylated bands. Similar results were observed with FRTL-5 Cl 2 cells transformed by the v-ras oncogene (Fig. 7C). Conversely, the transfection of r-PTPeta in both transformed thyroid cell lines markedly decreased the tyrosine phosphorylation of some bands; in some cases the transfection of r-PTPeta in the transformed rat thyroid cells resulted in the appearance of some hyperphosphorylated bands. No changes in the pattern of tyrosine phosphorylation were observed when PC MPSV cells were transfected with the the r-PTPeta C/S mutant construct (Fig. 2B). In summary, the reexpression of r-PTPeta drastically modified the tyrosine phosphorylation pattern of transformed thyroid cells.


View larger version (42K):
[in this window]
[in a new window]
  		FIG. 7.   Western blot analyses of tyrosine phosphorylation patterns in normal, transformed, and r-PTPeta -transfected thyroid cells. (A) Western blot analysis of PC Cl 3, PC MPSV, and PC MPSV/r-PTPeta C/S cells using an antiphosphotyrosine (anti-P-Tyr)-specific antibody. (B) Western blot analysis of PC MPSV and PC MPSV/r-PTPeta C/S cells with an anti-P-Tyr-specific antibody. (C) Western blot analysis of FRTL-5, FRTL KiMSV, and FRTL KiMSV/r-PTPeta cells using an anti-P-Tyr-specific antibody. Total proteins extracted from cells, as indicated, were separated (40 µg/lane) by SDS-PAGE and transferred to PVDF membranes. Western blots were incubated first with antibodies against P-Tyr and then with horseradish peroxidase-conjugated secondary antibodies; the immunocomplexes were detected by enhanced chemiluminescence. As a control for equal loading, the filters were stained with Ponceau red. Open arrows, bands with decreased tyrosine phosphorylation; solid arrows, hyperphosphorylated bands.

Reversion of the malignant phenotype by the r-PTPeta gene is associated with increased p27Kip1 protein levels. The reduced growth potential shown by PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells compared with that shown by PC MPSV and FRTL KiMSV cells, together with the finding that r-PTPeta partially restored mechanisms of growth control such as those leading to contact inhibition, suggested that r-PTPeta could directly or indirectly regulate the expression or the activity of cell cycle proteins. The observation that PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells presented more-pronounced fractions of G1 cells prompted us to analyze the expression and activity of G1 cyclin-dependent kinases (CDK2, CDK4, and CDK6) and of their inhibitors (p21Cip1, p27Kip1, and p57Kip2) in transformed and r-PTPeta -reverted cells. As shown in Fig. 8A, there was a significant increase of p27Kip1 protein levels in PC MPSV (almost 3-fold) and FRTL KiMSV (almost 2.5-fold) cell lines expressing the wild-type exogeneous r-PTPeta gene. p27Kip1 levels did not change significantly in the PC MPSV and FRTL KiMSV cells transfected with the backbone vector or the mutated r-PTPeta construct. Nor was there any change in p21Cip1 and p27Kip2 mRNA and protein levels in reverted cells compared with those in PC MPSV and FRTL KiMSV cells (Fig. 8A and data not shown).


View larger version (36K):
[in this window]
[in a new window]
  		FIG. 8.   Northern and Western blot analyses of p27Kip1 gene and protein expression in normal, transformed, and r-PTPeta -transfected thyroid cells. (A) Western blot analysis. Proteins extracted from normal, transformed, and r-PTPeta -transfected cells were separated (20 µg/lane) by SDS-PAGE, transferred to PVDF membranes, and analyzed with the indicated antibodies by Western blotting. As a control for equal loading, the blotted proteins were stained with Ponceau red. The sources of proteins are indicated. (B) Northern blot analysis. Total RNA (20 µg/lane) extracted from normal, transformed, and r-PTPeta -transfected cells was hybridized to p27Kip1 radiolabeled cDNA and then to a rat GAPDH gene probe, as a control for RNA loading. The sources of RNAs are indicated. (C) Inhibition of proteasome by LLNL (LLN) stabilizes p27Kip1 protein levels. PC MPSV and FRTL KiMSV cells were treated with 50 µM LLNL proteasome inhibitor or with solvent alone (dimethyl sulfoxide) for 12 h. Cells were then lysed, and p27Kip1 expression was analyzed by Western blotting. Arrows, p27Kip1 or a monoubiquitinated form of p27 (Ubi-p27) in LLNL-treated cells. (D) In vitro p27Kip1 degradation assay. One microgram of recombinant p27Kip1 protein was incubated with 100 µg of proteasome extracts from PC Cl 3, PC MPSV, and PC MPSV/r-PTPeta cells (left) or from FRTL-5 Cl 2, FRTL KiMSV, and FRTL KiMSV/r-PTPeta cells (right) for 12 h and then loaded onto a 12.5% polyacrylamide gel, transferred to nitrocellulose membranes, and revealed by anti-p27Kip1 antibodies. Lane 1, the recombinant p27Kip1 protein was incubated in the absence of cell extracts. The sources of cell extracts are indicated.

The finding that p27Kip1 mRNA levels were not modified by r-PTPeta expression (Fig. 8B) suggested that posttranslational mechanisms may account for the increased levels of p27Kip1 protein in the wild-type r-PTPeta -transfected cells. Since p27Kip1 expression is regulated at the posttranslational level (32), we investigated whether an inhibitor of the 26S proteasome was able to up-regulate p27 expression in v-ras-Ki- or v-mos-transformed cells. PC MPSV and FRTL KiMSV cells were treated with a 50 µM concentration of the proteasome inhibitor peptide aldehyde N-acetyl-leucinyl-leucinyl-norleucinal (LLNL) or the related inactive compound N-methyl-leucinyl-leucinyl-methioninal. As shown in Fig. 8C, inhibition of the proteasome by LLNL resulted in stabilization of the p27Kip1 protein. This provided experimental evidence that the proteasome pathway is involved in p27Kip1 regulation in v-ras-Ki- and v-mos-transformed cells. Finally, the accumulation in LLNL-treated cells of a high-molecular-weight form of p27Kip1, a monoubiquitinated form of p27 (32), suggests that p27Kip1 is ubiquitinated in PC MPSV and FRTL KiMSV cells. We also investigated the rate of p27Kip1 degradation in normal, transformed, and r-PTPeta -transfected cells by performing a p27Kip1 degradation assay (see Materials and Methods). As shown in Fig. 8D, proteasome extracts from PC MPSV and FRTL KiMSV cells with low levels of p27 expression degraded exogenous recombinant p27Kip1 more rapidly than those from parental PC Cl 3 and FRTL-5 Cl 2 cell lines (4- and 3.3-fold, respectively). Expression of r-PTPeta in transformed thyroid cells significantly reduced (about twofold) the rate of p27Kip1 degradation (Fig. 8D). No effect on p27 stabilization was achieved by the expression of the r-PTPeta C/S mutant, demonstrating that it is specifically induced by a signal sent by r-PTPeta phosphatase activity. These findings demonstrate that a transmembrane tyrosine phosphatase is able to govern the level of CDK inhibitor p27Kip1 by regulating p27Kip1 protein turnover. This effect was specific for the p27Kip1 protein, since it was not observed with the recombinant p21Cip1 (data not shown).

r-PTPeta decreases MAP kinase activity in FRTL KiMSV and PC MPSV cells. Since our results demonstrate that v-ras- and v-mos-transformed thyroid cells showed increased p27Kip1 protein turnover, we investigated whether the MAP kinase pathway, which is activated by v-ras-Ki and v-mos, mediated this effect. Western blot analysis with antibodies that recognize either the phosphorylated (Fig. 9A, top) or the total (Fig. 9A, bottom) ERK1 and -2 proteins demonstrated that v-ras-Ki and v-mos oncogenes weakly increased total protein levels of ERK1 and -2 in transformed thyroid cells: 2- and 1.4-fold increases in the total ERK1 and -2 level in PC MPSV and FRTL KiMSV cells compared with levels in PC Cl 3 and FRTL-5 Cl 2 cells, respectively, were observed. Expression of the v-mos oncogene induced a significant increase in the phosphorylation of ERK1 and -2 (32% of ERK1 and -2 was phosphorylated in PC MPSV cells compared with 9% in PC Cl 3 cells). Equally, in FRTL KiMSV cells, was the degree of ERK1 and -2 phosphorylation was 29%, whereas only 9% of total ERK1 and -2 was phosphorylated in normal cells. Strikingly, we found that r-PTPeta expression reduced phosphorylation of ERK1 and -2 in FRTL KiMSV and PC MPSV cells almost to basal levels: ERK1 and -2 phosphorylation was reduced to 11% in PC MPSV/r-PTPeta cells and to 14% in FRTL KiMSV/r-PTPeta cells.


View larger version (37K):
[in this window]
[in a new window]
  		FIG. 9.   Reduction of MAP kinase activity in r-PTPeta -transfected thyroid cells results in up-regulation of p27Kip1 expression. (A) Western blot analysis of phosphorylated and total protein level of ERK1 and -2. Proteins extracted from normal, transformed, and r-PTPeta transfected cells were separated (20 µg/lane) by SDS-PAGE, transferred to PVDF membranes, and analyzed with the indicated antibodies by Western blotting. (Top) the antibody used detected phosphorylated ERK1 and -2; (bottom) the antibody used detected total ERK1 and -2. (B) Inhibition of the MAP kinase pathway up-regulates p27Kip1 expression. (Top) Western blot analysis of p27Kip1 protein in untreated PC MPSV (lane 1) and FRTL KiMSV (lane 4) cells or in cells treated for 8 h with MEK inhibitor PD93059 (lanes 2 and 5, respectively) or solvent (dimethyl sulfoxide [DMSO]) alone (lanes 3 and 6, respectively); (middle) Western blot analysis of phosphorylated ERK1 and -2; (bottom) Western blot analysis of total ERK1 and -2.

In rat fibroblasts, oncogenic Ras accelerates the degradation of p27Kip1 through the activation of the MAP kinase pathway (16). Thus, we investigated whether in malignant thyroid cells activation of the MAP kinase pathway could account for the reduced p27 expression. For this purpose, FRTL KiMSV and PC MPSV cells were treated for 8 h with 50 µM MAP kinase kinase (MEK) inhibitor PD98059 or solvent alone. Western blot analysis demonstrated that at that dose the expression of both (ERK1 and -2) was not modified (Fig. 9B, bottom) but that both ERK1 and -2 were in the unphosphorylated form and thus inactive (Fig. 9B, middle). Subsequent analysis of p27Kip1 protein levels in the same lysates showed that inhibition of the MAP kinase pathway induced a two- to threefold increase in p27Kip1 expression in v-mos- and in v-ras-Ki-transformed cells, respectively, after 8 h of treatment (Fig. 9B, top). This suggests that activation of the MAP kinase pathway is involved in v-ras-Ki and v-mos-dependent degradation of p27Kip1 in FRTL KiMSV and PC MPSV cells and that r-PTPeta expression restores p27Kip1 protein levels in transformed cells by suppressing ERK1 and -2 activation. These results indicate that the MAP kinase pathway, either directly or indirectly, regulates the level of p27Kip1 in transformed thyroid cells, and we propose that r-PTPeta may regulate expression of p27Kip1 by modulating the activity of the MAP kinase pathway.

The block of p27Kip1 protein synthesis by antisense-specific oligonucleotides prevents r-PTPeta -induced growth arrest. To test the hypothesis that p27Kip1 mediates r-PTPeta -induced reversion of the malignant thyroid cells, we transfected PC MPSV and FRTL KiMSV cells with a vector expressing p27Kip1 cDNA. The number of colonies after 14 days was drastically reduced in the malignant cells versus those transfected with backbone vectors (data not shown). When the same assay was performed with the r-PTPeta construct, the number of colonies was similar to that obtained with the p27Kip1 construct (Table 2). There was no growth inhibition when the same cells were transfected with the r-PTPeta C/S construct or the empty vector (data not shown). To verify that the r-PTPeta -induced growth arrest was mediated by up-regulation of the p27Kip1 protein, a colony assay of PC MPSV and FRTL KiMSV cells was performed with antisense oligonucleotides corresponding to the 5' end of the p27Kip1 gene. These oligonucleotides blocked p27Kip1 synthesis in the transformed cells (Fig. 10B). As shown in Table 2 and in Fig. 10, blockage of p27Kip1 synthesis prevented the growth arrest induced by r-PTPeta . Conversely, the r-PTPeta gene greatly reduced the number of colonies in the presence of p27Kip1 sense oligonucleotides.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Colony-forming assay by transfecting the r-PTPeta gene into PC MPSV and FRTL KiMSV cells in the presence of sense or antisense p27 oligonucleotides



View larger version (49K):
[in this window]
[in a new window]
  		FIG. 10.   Colony assay of r-PTPeta transfection in PC MPSV cells. PC MPSV cells were transfected with a vector expressing r-PTPeta cDNA in the presence of antisense oligonucleotides corresponding to the 5' end of the p27Kip1 gene. The cells were selected for resistance to G418, and colonies were the counted after 14 days. (A) PC MPSV cells transfected with control backbone vector (left), PC MPSV cells transfected with r-PTPeta (middle), and PC MPSV cells transfected with r-PTPeta in the presence of antisense p27Kip1 oligonucleotides (AS) (right). (B) Western blot analysis of p27Kip1 and r-PTPeta expression in PC MPSV cells transfected with the backbone vector (left lane), r-PTPeta (middle lane), or r-PTPeta in the presence of antisense p27Kip1 oligonucleotides (right lane). Anti-gamma -tubulin antibodies were used to assure uniform loading of lanes.

Analogous results were obtained by a complementary approach. In fact, we measured the rates of BrdU incorporation in PC MPSV/r-PTPeta cells and FRTL KiMSV/r-PTPeta cells and in the same cells treated with antisense oligonucleotides against p27Kip1. In this case, cells were plated, treated for 24 h with 10 µM p27Kip1 antisense phosphorothioate oligonucleotide or with the same dose of a control oligonucleotide with a similar base content but a scrambled sequence, incubated with BrdU for 1 h, and then processed for indirect immunofluorescence. PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells showed 15.5 and 15.8% BrdU incorporation, respectively. Similar results were obtained if these cell lines were treated with the control scrambled oligonucleotide (20.6% of PC MPSV/r-PTPeta cells and 17.4% of FRTL KiMSV/r-PTPeta cells incorporated BrdU). Conversely, both PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells treated with anti-p27 antisense oligonucleotides showed markedly increased rates of BrdU uptake (37.3 and 29.2%, respectively).

These results indicate that the p27Kip1 protein is required for the growth arrest induced by r-PTPeta in transformed cells.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

DEP-1 expression is drastically reduced in human thyroid tumors. We previously demonstrated that the expression of rat protein tyrosine phosphatase eta  (49), because of the homology of the protein with DEP-1/HPTPeta (14, 31), is down-regulated in transformed rat thyroid cells. Here, we show that the level of the DEP-1/HPTPeta protein was dramatically reduced in a large number of human thyroid carcinomas regardless of histological origin. This indicates that reduction in DEP-1/HPTPeta expression is a general event in human thyroid carcinogenesis and suggests that the r-PTPeta gene may act as a tumor suppressor gene (49).

Growth suppressor activity of r-PTPeta . To ascertain whether r-PTPeta suppresses neoplastic cell growth, we introduced a retroviral vector carrying the r-PTPeta gene into malignant rat thyroid cell lines PC MPSV and FRTL KiMSV, which have lost endogenous r-PTPeta expression. These cells were generated by infecting normal rat thyrocytes (PC Cl 3 and FRTL-5 Cl 2 cells, respectively) with retroviruses carrying the v-mos and the v-ras-Ki oncogenes (9, 10). Both cell lines are morphologically transformed in vitro, have lost all molecular markers of thyroid differentiation expression, and are highly tumorigenic in vivo. Transfection of PC MPSV or FRTL KiMSV cells with the r-PTPeta gene causes the loss of the malignant phenotype. In fact, both PC MPSV/r-PTPeta or FRTL KiSV/r-PTPeta cells lost the ability to grow in soft agar and to induce tumors after injection into athymic mice. The finding that no reversion was observed with a construct that carries the r-PTPeta gene with a point mutation in the catalytic region (r-PTPeta C/S) demonstrates that the catalytic domain is required for its growth-inhibiting activity. No reversion was achieved when the PC MPSV and FRTL KiMSV cells were transfected with the PTPgamma gene; consequently, the tumor suppressor activity shown by r-PTPeta cannot be considered a general effect of receptor-type PTPs. It is worthwhile to mention that activation of ras genes (including the c-ras-Ki oncogene) is a frequent finding in human thyroid carcinomas of the follicular and anaplastic histotypes and is found less frequently in papillary thyroid carcinomas (37).

The cyclin-dependent kinase inhibitor p27Kip1 mediates PTPeta growth-inhibitory activity in rat thyroid cells. The reduced growth potential of PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells compared with that of PC MPSV and FRTL KiMSV cells, respectively, together with the finding that r-PTPeta partially restores control growth mechanisms (i.e., contract inhibition), suggested that r-PTPeta could regulate the expression or the activity of cell cycle proteins. Western blot analysis revealed that, in both PC MPSV/r-PTPeta and FRTL KiMSV/r-PTPeta cells, there was an increase in the steady-state levels of the cyclin-dependent kinase inhibitor p27Kip1, a CDK inhibitor linked to G1 arrest in contact-inhibited cells (33, 39, 44). Conversely, the p21Cip1 and p57Kip2 levels remained unchanged. The observation that the human homolog of r-PTPeta , DEP-1/HPTPeta , and p27Kip1 are up-regulated by increased cell density (14, 31, 33) suggests a correlation between their expression. We provide experimental evidence that the growth-inhibiting activity exerted by r-PTPeta on thyroid cells depends on the p27Kip1 levels. In fact, as with r-PTPeta , the transfection of a p27Kip1 expression vector into PC MPSV or FRTL KiMSV cells suppresses their growth (data not shown); specific p27Kip1 gene antisense oligonucleotides which inhibit p27Kip1 protein synthesis greatly reduced the growth-suppressing activity of r-PTPeta on PC MPSV and FRTL KIMSV cells.

The molecular mechanism whereby PTPeta regulates the p27Kip1 degradation rate involves control of MAP kinase activity. A relevant finding of our work is that a membrane tyrosine phosphatase, the r-PTPeta protein, is able to modulate the expression levels of cell cycle modulators, such as p27Kip1. In transformed rat thyroid cells we observed a decreased amount of p27Kip1 protein, even though the mRNA levels were not different from those of parental cells. An increased proteolytic degradation of p27Kip1 through the 26S proteasome in v-ras-Ki and v-mos-transformed cells accounts for this result.

Our results suggest that activation of the MAP kinase pathway is involved in p27Kip1 proteolytic degradation induced by v-ras-Ki and v-mos. In fact, we found that in PC MPSV and FRTL KiMSV cells, the activity of the MAP kinase pathway is increased in parallel with a decrease in the level of p27Kip1 protein; moreover, chemical inhibition of MAP kinases by MEK inhibitor PD93059 up-regulated p27Kip1 in both PC MPSV and FRTL KiMSV cells. These observations are in agreement with the finding that in rat fibroblasts Ras-activated ERK1 and -2 phosphorylate p27Kip1, thus resulting in decreased p27Kip1 expression and decreased capability to bind and inhibit CDK2 (16).

Restoration of r-PTPeta expression in transformed thyroid cells inhibited MAP kinase activation by v-ras-Ki and v-mos, resulting in increased p27Kip1 expression and in a reduction of the growth rate of oncogene-transformed cells. Taken together, these results suggest that, in rat thyroid cells, v-ras-Ki and v-mos target p27Kip1 to proteolytic degradation by activating the MAP kinase pathway and that r-PTPeta regulates p27Kip1 stability by preventing MAP kinase activation.

Interestingly, it has been recently shown that two tyrosine phosphatases, PTP-SL and STEP, inhibit MAP kinase activation by associating with and dephosphorylating a tyrosine residue on ERK1 and -2 (34). PTP-SL and STEP contain at the N terminus a MAP kinase binding domain of 16 amino acids which is responsible for MAP kinase association. The r-PTPeta protein does not contain such MAP kinase binding domain. This suggests a different mechanism of action, but it does not rule out the possibility that the r-PTPeta protein may bind to MAP kinases through a different interaction domain.

Perspectives and conclusions. The loss of DEP-1/HPTPeta gene expression in human thyroid carcinomas and the tumor suppressor activity exerted by r-PTPeta in rat thyroid cells suggest the fascinating perspective of a gene therapy based on the targeted expression of the r-PTPeta gene through appropriate vectors for the treatment of anaplastic thyroid carcinomas which are unresponsive to conventional therapy and which invariably lead to death in few months.

In conclusion, the r-PTPeta gene exerts growth inhibition activity in transformed thyroid cells, which appears to be mediated by the stabilization of the cyclin-dependent kinase inhibitor p27Kip1.


    ACKNOWLEDGMENTS

This work was supported by grants from AIRC (Progetto Speciale Oncosoppressori), from the Progetto Finalizzato Biotecnologie of the CNR, the MURST projects Terapie antineoplastiche innovative and Piani di Potenziamento della Rete Scientifica e Tecnologica, and from the Ministero della Sanità. We thank the Associazione Partenopea per la Ricerche Oncologiche (APRO) for its support. Francesco Trapasso, Paola Bruni, Angelo Boccia, Gustavo Baldassarre, and Antonella Stella were recipients of a fellowship from the Fondazione Italiana per la Ricerca sul Cancro (FIRC).

We are grateful to Jean Gilder for editing the text.


    FOOTNOTES

* Corresponding author. Mailing address: Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II," via Pansini 5, 80131 Naples, Italy. Phone: 39 081 7463056. Fax: 39 081 7463037. E-mail: afusco{at}napoli.com.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Baldassarre, G., B. Belletti, S. Spiezia, P. Bruni, F. Trapasso, F. Pentimalli, M. V. Barone, G. Chiappetta, M. T. Vento, A. Boccia, A. Fusco, and G. Viglietto. 1999. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J. Clin. Investig. 104:865-874[Medline].
2. Berlingieri, M. T., G. Manfioletti, M. Santoro, A. Bandiera, R. Visconti, V. Giancotti, and A. Fusco. 1995. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol. Cell. Biol. 15:1545-1553[Abstract].
3. Brady-Kalnay, S. M., D. L. Rimm, and N. K. Tonks. 1995. Receptor protein tyrosine phosphatase PTPmu associates with cadherins and catenins in vivo. J. Cell Biol. 130:977-986[Abstract/Free Full Text].
4. Brown-Shimer, S., K. A. Johnson, D. E. Hill, and A. M. Bruskin. 1992. Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene. Cancer Res. 52:478-482[Abstract/Free Full Text].
5. Coats, S., W. M. Flanagan, J. Nourse, and J. M. Roberts. 1996. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272:877-880[Abstract].
6. de Vries-Smitts, A. M. M., B. M. T. Burgering, S. J. Leevers, C. J. Marshall, and J. L. Boss. 1992. Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature 357:602-604[CrossRef][Medline].
7. Fuchs, M., T. Mueller, M. M. Lerch, and A. Ullrich. 1996. Association of human protein-tyrosine phosphatase kappa with members of the armadillo family. J. Biol. Chem. 271:16712-16719[Abstract/Free Full Text].
8. Furnari, F. B., H. Lin, H. S. Huang, and W. K. Cavenee. 1997. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. USA 94:12479-12484[Abstract/Free Full Text].
9. Fusco, A., G. Portella, P. P. Di Fiore, M. T. Berlingieri, R. Di Lauro, A. B. Schneider, and G. Vecchio. 1985. A mos oncogene-containing retrovirus, myeloproliferative sarcoma virus, transforms rat thyroid epithelial cells and irreversibly blocks their differentiation pattern. J. Virol. 56:284-292[Abstract/Free Full Text].
10. Fusco, A., M. T. Berlingieri, P. P. Di Fiore, G. Portella, M. Grieco, and G. Vecchio. 1987. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell. Biol. 7:3365-3370[Abstract/Free Full Text].
11. Goldsmith, B. A., and S. Koizumi. 1997. Protein tyrosine phosphatases: positive and negative regulation of proliferation. Int. J. Oncol. 11:825-834.
12. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of the infectivity of human adenovirus 5 DNA. Virology 52:456-467[CrossRef][Medline].
13. Higuchi, R. 1990. Recombinant PCR, p. 177-183. In M. A. Innis, D. H. Gelfand, J. J. Sninski, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, Inc., San Diego, Calif.
14. Honda, H., J. Inazawa, J. Nishida, Y. Yazaki, and H. Hirai. 1994. Molecular cloning, characterization, and chromosomal localization of a novel protein tyrosine phosphatase, HPTPeta . Blood 84:4186-4194[Abstract/Free Full Text].
15. Hunter, T., and J. A. Cooper. 1985. Protein-tyrosine kinases. Annu. Rev. Biochem. 54:897-930[Medline].
16. Kawada, M., S. Yamagoe, T. Y. Murakami, K. Suzuki, S. Mizuno, and Y. Uheara. 1997. Induction of p27 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15:629-637[CrossRef][Medline].
17. Keane, M. M., G. A. Lowrey, S. A. Ettemberg, M. A. Dayton, and S. Lipkowitz. 1996. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res. 56:4236-4243[Abstract/Free Full Text].
18. Krishan, A. 1975. Rapid flow cytofluorimetric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 66:188-193[Abstract/Free Full Text].
19. Kuramochi, S., S. Matsuda, Y. Matsuda, T. Saitoh, M. Ohsugi, and T. Yamamoto. 1996. Molecular cloning and characterization of Byp, a murine receptor-type tyrosine phosphatase similar to human DEP-1. FEBS Lett. 378:7-14[CrossRef][Medline].
20. LaForgia, S., B. Morse, J. Levy, G. Barnea, L. A. Cannizzaro, F. Li, P. C. Nowell, L. Boghosian-Sell, J. Glick, and A. Weston. 1991. Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21. Proc. Natl. Acad. Sci. USA 88:5036-5040[Abstract/Free Full Text].
21. Li, J., C. Yen, D. Liaw, K. Podsypanina, S. Bose, S. J. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S. H. Bigner, B. C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M. H. Wigler, and R. Parson. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947[Abstract/Free Full Text].
22. Liaw, D., D. J. Marsh, J. Li, P. L. Dahia, S. I. Wang, Z. Zheng, S. Bose, M. M. Call, H. C. Tsou, M. Peacocke, C. Eng, and R. Parsons. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16:64-67[CrossRef][Medline].
23. Loda, M., B. Cukor, S. W. Tam, P. Lavin, M. Fiorentino, G. Draetta, J. M. Jessup, and M. Pagano. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:231-234[CrossRef][Medline].
24. MacPherson, I., and I. Montagnier. 1964. Agar suspension culture for the selective assay of cells transformed by polyoma virus. Virology 23:291-294[CrossRef][Medline].
25. Maddon, P. J., A. G. Dalgleish, J. S. McDougal, P. R. Clapham, R. Weiss, and R. Axel. 1986. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333-348[CrossRef][Medline].
26. Marsh, D. J., P. L. Dahia, Z. Zheng, D. Liaw, R. Parsons, R. J. Gorlin, and C. Eng. 1997. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Natl. Genet. 16:333-334.
27. Marsh, D. J., V. Coulon, K. L. Lunetta, P. Rocca-Serra, P. L. Dahia, Z. Zheng, D. Liaw, S. Caron, B. Duboue, A. Y. Lin, A. L. Richardson, J. M. Bonnetblanc, J. M. Bressieux, A. Cabarrot-Moreau, A. Chompret, L. Demange, R. A. Eeles, A. M. Yahanda, E. R. Fearon, J. P. Fricker, R. J. Gorlin, S. V. Hodgson, S. Huson, D. Lacombe, and C. Eng. 1998. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 7:507-515[Abstract/Free Full Text].
28. Martelli, M. L., F. Trapasso, P. Bruni, M. T. Berlingieri, C. Battaglia, M. T. Vento, B. Belletti, R. Iuliano, M. Santoro, G. Viglietto, and A. Fusco. 1998. Protein tyrosine phosphatase-eta expression is upregulated by the PKC-dependent and is downregulated by the PKC-dependent pathways in thyroid cells. Exp. Cell Res. 245:195-202[CrossRef][Medline].
29. Myers, M. P., J. P. Stolarov, C. Eng, J. Li, S. I. Wang, M. H. Wigler, R. Parsons, and N. K. Tonks. 1997. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. USA 94:9052-9057[Abstract/Free Full Text].
30. Okazaki, K., and N. Sagato. 1995. MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos. EMBO J. 14:5048-5059[Medline].
31. Ostman, A., Q. Yang, and N. K. Tonks. 1994. Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density. Proc. Natl. Acad. Sci. USA 91:9680-9684[Abstract/Free Full Text].
32. Pagano, M., S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe. 1995. Role of the ubiquitin proteasome pathway in regulating abundance of the cyclin-dependent inhibitor p27. Science 267:1024-1027[Abstract/Free Full Text].
33. Polyak, K., J. Kato, M. J. Solomon, C. J. Sherr, J. Massagué, J. M. Roberts, and A. Koff. 1994. p27kip1, a cyclin-CDK inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22[Abstract/Free Full Text].
34. Pulido, R., A. Zuniga, and A. Ullrich. 1998. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J. 17:7337-7350[CrossRef][Medline].
35. Robbins, D. J., M. Cheng, E. Zhen, C. A. Vanderbilt, L. A. Feig, and M. H. Cobb. 1992. Evidence for a Ras-dependent extracellular signal-regulated protein kinase (ERK) cascade. Proc. Natl. Acad. Sci. USA 89:6924-6928[Abstract/Free Full Text].
36. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
37. Santoro, M., M. Grieco, R. M. Melillo, A. Fusco, and G. Vecchio. 1995. Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur. J. Endocrinol. 133:513-522[Abstract/Free Full Text].
38. Sherr, C. J., and J. Roberts. 1995. Inhibitors of mammalian G1 cyclin dependent kinases. Genes Dev. 9:1149-1163[Free Full Text].
39. Soos, T. J., H. Kiyokawa, J. S. Yan, M. S. Rubin, A. Giordano, A. DeBlasio, S. Bottega, B. Wong, J. Mendelsohn, and A. Koff. 1996. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 7:135-146[Abstract].
40. Sorio, C., P. Melotti, D. D'Arcangelo, J. Mendrola, B. Calabretta, C. M. Croce, and K. Huebner. 1997. Receptor protein tyrosine phosphatase gamma, Ptpgamma , regulates hematopoietic differentiation. Blood 90:49-57[Abstract/Free Full Text].
41. Steck, P. A., M. A. Pershouse, S. A. Jasser, W. K. Yung, H. Lin, A. H. Ligon, L. A. Langford, M. L. Baumgard, T. Hattier, T. Davis, C. Frye, R. Hu, B. Swedlund, D. H. Teng, and S. V. Tavtigian. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:356-362[CrossRef][Medline].
42. Thomas, S. M., M. De Marco, G. D'Arcangelo, S. Halegou, and J. S. Brugge. 1992. Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases. Cell 68:1031-1040[CrossRef][Medline].
43. Tonks, N. K., and B. G. Neel. 1996. From form to function: signaling by protein tyrosine phosphatase. Cell 87:365-368[CrossRef][Medline].
44. Toyoshima, H., and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74[CrossRef][Medline].
45. Ullrich, A., and J. Schlessinger. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212[CrossRef][Medline].
46. van der Geer, P., T. Hunter, and R. A. Lindberg. 1994. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 10:251-337[CrossRef].
47. Zannini, M. S., H. Francis-Lang, D. Plachov, and R. Di Lauro. 1992. Pax-8, a paired domain-containing protein, binds to sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters. Mol. Cell. Biol. 12:4230-4241[Abstract/Free Full Text].
48. Zhai, Y., J. Wirth, S. Kang, C. W. Welsch, and W. J. Esselman. 1995. LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells. Mol. Carcinog. 14:103-110[Medline].
49. Zhang, L., M. L. Martelli, C. Battaglia, F. Trapasso, D. Tramontano, G. Viglietto, A. Porcellini, M. Santoro, and A. Fusco. 1997. Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. Exp. Cell Res. 235:62-70[CrossRef][Medline].

Molecular and Cellular Biology, December 2000, p. 9236-9246, Vol. 20, No. 24
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Sacco, F., Tinti, M., Palma, A., Ferrari, E., Nardozza, A. P., van Huijsduijnen, R. H., Takahashi, T., Castagnoli, L., Cesareni, G. (2009). Tumor Suppressor Density-enhanced Phosphatase-1 (DEP-1) Inhibits the RAS Pathway by Direct Dephosphorylation of ERK1/2 Kinases. J. Biol. Chem. 284: 22048-22058 [Abstract] [Full Text]  
  • Fedele, M., Palmieri, D., Chiappetta, G., Pasquinelli, R., De Martino, I., Arra, C., Palma, G., Valentino, T., Pierantoni, G. M, Viglietto, G., Rothstein, J. L, Santoro, M., Fusco, A. (2009). Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. Endocr Relat Cancer 16: 483-490 [Abstract] [Full Text]  
  • Sallee, J. L., Burridge, K. (2009). Density-enhanced Phosphatase 1 Regulates Phosphorylation of Tight Junction Proteins and Enhances Barrier Function of Epithelial Cells. J. Biol. Chem. 284: 14997-15006 [Abstract] [Full Text]  
  • Iuliano, R., Raso, C., Quintiero, A., Pera, I. L., Pichiorri, F., Palumbo, T., Palmieri, D., Pattarozzi, A., Florio, T., Viglietto, G., Trapasso, F., Croce, C. M., Fusco, A. (2009). The Eighth Fibronectin Type III Domain of Protein Tyrosine Phosphatase Receptor J Influences the Formation of Protein Complexes and Cell Localization. J Biochem 145: 377-385 [Abstract] [Full Text]  
  • Chabot, C., Spring, K., Gratton, J.-P., Elchebly, M., Royal, I. (2009). New Role for the Protein Tyrosine Phosphatase DEP-1 in Akt Activation and Endothelial Cell Survival. Mol. Cell. Biol. 29: 241-253 [Abstract] [Full Text]  
  • Barbieri, F., Pattarozzi, A., Gatti, M., Porcile, C., Bajetto, A., Ferrari, A., Culler, M. D., Florio, T. (2008). Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferation in Vitro via a Phosphotyrosine Phosphatase-{eta}-Dependent Inhibition of Extracellularly Regulated Kinase-1/2. Endocrinology 149: 4736-4746 [Abstract] [Full Text]  
  • Karagyozov, L., Godfrey, R., Bohmer, S.-A., Petermann, A., Holters, S., Ostman, A., Bohmer, F.-D. (2008). The structure of the 5'-end of the protein-tyrosine phosphatase PTPRJ mRNA reveals a novel mechanism for translation attenuation. Nucleic Acids Res 36: 4443-4453 [Abstract] [Full Text]  
  • Arena, S., Pattarozzi, A., Massa, A., Esteve, J.-P., Iuliano, R., Fusco, A., Susini, C., Florio, T. (2007). An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase {eta}. Mol. Endocrinol. 21: 229-246 [Abstract] [Full Text]  
  • Takahashi, T., Takahashi, K., Mernaugh, R. L., Tsuboi, N., Liu, H., Daniel, T. O. (2006). A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis. Blood 108: 1234-1242 [Abstract] [Full Text]  
  • Iervolino, A., Iuliano, R., Trapasso, F., Viglietto, G., Melillo, R. M., Carlomagno, F., Santoro, M., Fusco, A. (2006). The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins.. Cancer Res. 66: 6280-6287 [Abstract] [Full Text]  
  • Baumer, S., Keller, L., Holtmann, A., Funke, R., August, B., Gamp, A., Wolburg, H., Wolburg-Buchholz, K., Deutsch, U., Vestweber, D. (2006). Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. Blood 107: 4754-4762 [Abstract] [Full Text]  
  • Lesueur, F., Pharoah, P. D., Laing, S., Ahmed, S., Jordan, C., Smith, P. L., Luben, R., Wareham, N. J., Easton, D. F., Dunning, A. M., Ponder, B. A.J. (2005). Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet 14: 2349-2356 [Abstract] [Full Text]  
  • Berset, T. A., Hoier, E. F., Hajnal, A. (2005). The C. elegans homolog of the mammalian tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to regulate binary cell fate decisions. Genes Dev. 19: 1328-1340 [Abstract] [Full Text]  
  • Trapasso, F., Yendamuri, S., Dumon, K. R., Iuliano, R., Cesari, R., Feig, B., Seto, R., Infante, L., Ishii, H., Vecchione, A., During, M. J., Croce, C. M., Fusco, A. (2004). Restoration of receptor-type protein tyrosine phosphatase {eta} function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis 25: 2107-2114 [Abstract] [Full Text]  
  • Lin, J., Zhu, J. W., Baker, J. E., Weiss, A. (2004). Regulated Expression of the Receptor-Like Tyrosine Phosphatase CD148 on Hemopoietic Cells. J. Immunol. 173: 2324-2330 [Abstract] [Full Text]  
  • Massa, A., Barbieri, F., Aiello, C., Arena, S., Pattarozzi, A., Pirani, P., Corsaro, A., Iuliano, R., Fusco, A., Zona, G., Spaziante, R., Florio, T., Schettini, G. (2004). The Expression of the Phosphotyrosine Phosphatase DEP-1/PTP{eta} Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation. J. Biol. Chem. 279: 29004-29012 [Abstract] [Full Text]  
  • Lund, I. K., Andersen, H. S., Iversen, L. F., Olsen, O. H., Moller, K. B., Pedersen, A. K., Ge, Y., Holsworth, D. D., Newman, M. J., Axe, F. U., Moller, N. P. H. (2004). Structure-based Design of Selective and Potent Inhibitors of Protein-tyrosine Phosphatase {beta}. J. Biol. Chem. 279: 24226-24235 [Abstract] [Full Text]  
  • Kuroki, T., Yendamuri, S., Trapasso, F., Matsuyama, A., Aqeilan, R. I., Alder, H., Rattan, S., Cesari, R., Nolli, M. L., Williams, N. N., Mori, M., Kanematsu, T., Croce, C. M. (2004). The Tumor Suppressor Gene WWOX at FRA16D Is Involved in Pancreatic Carcinogenesis. Clin. Cancer Res. 10: 2459-2465 [Abstract] [Full Text]  
  • Lampugnani, M. G., Zanetti, A., Corada, M., Takahashi, T., Balconi, G., Breviario, F., Orsenigo, F., Cattelino, A., Kemler, R., Daniel, T. O., Dejana, E. (2003). Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, {beta}-catenin, and the phosphatase DEP-1/CD148. JCB 161: 793-804 [Abstract] [Full Text]  
  • Takahashi, T., Takahashi, K., St. John, P. L., Fleming, P. A., Tomemori, T., Watanabe, T., Abrahamson, D. R., Drake, C. J., Shirasawa, T., Daniel, T. O. (2003). A Mutant Receptor Tyrosine Phosphatase, CD148, Causes Defects in Vascular Development. Mol. Cell. Biol. 23: 1817-1831 [Abstract] [Full Text]  
  • Iuliano, R., Trapasso, F., Le Pera, I., Schepis, F., Sama, I., Clodomiro, A., Dumon, K. R., Santoro, M., Chiariotti, L., Viglietto, G., Fusco, A. (2003). An Adenovirus Carrying the Rat Protein Tyrosine Phosphatase {eta} Suppresses the Growth of Human Thyroid Carcinoma Cell Lines in Vitro and in Vivo. Cancer Res. 63: 882-886 [Abstract] [Full Text]  
  • Palka, H. L., Park, M., Tonks, N. K. (2003). Hepatocyte Growth Factor Receptor Tyrosine Kinase Met Is a Substrate of the Receptor Protein-tyrosine Phosphatase DEP-1. J. Biol. Chem. 278: 5728-5735 [Abstract] [Full Text]  
  • Florio, T., Arena, S., Thellung, S., Iuliano, R., Corsaro, A., Massa, A., Pattarozzi, A., Bajetto, A., Trapasso, F., Fusco, A., Schettini, G. (2001). The Activation of the Phosphotyrosine Phosphatase {eta} (r-PTP{eta}) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation. Mol. Endocrinol. 15: 1838-1852 [Abstract] [Full Text]  
  • Choudhury, G. G. (2001). Akt Serine Threonine Kinase Regulates Platelet-derived Growth Factor-induced DNA Synthesis in Glomerular Mesangial Cells. REGULATION OF c-fos AND p27kip1 GENE EXPRESSION. J. Biol. Chem. 276: 35636-35643 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trapasso, F.
Right arrow Articles by Fusco, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trapasso, F.
Right arrow Articles by Fusco, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»